is retatrutide fda approved october 2025 approves this year? Predictions & Odds 2026 FDA Warns Companies Over Compounded

Individuals with any of the following conditions should consult with their healthcare provider before use and may not be eligible for treatment: Personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN2) Known hypersensitivity to GLP-1 or GLP-1/GIP medications or any formulation components, including additives such as vitamin B12 or cobalt Pregnancy or plans to become pregnant (therapy should be discontinued at least two months prior to planned pregnancy) Diabetic ketoacidosis (DKA) or type 1 diabetes Severe gastrointestinal disease (including gastroparesis or active inflammatory bowel disease) Severe cardiovascular disease (including unstable coronary artery disease or heart failure) Recent bariatric or gastrointestinal surgery within the past six months Active cancer currently undergoing chemotherapy or radiation treatment This list is not comprehensive

Mild, transient erythema immediately after patch removal is common, but prolonged or severe reactions warrant medical review

Experts agree removing GLP-1s from the 503B bulks list will significantly lower the availability of compounded GLP-1s drugs

Retatrutides weight loss results are particularly noteworthy when compared to other therapies